|
KMID : 1148920070410020112
|
|
Nuclear Medicine and Molecular Imaging
2007 Volume.41 No. 2 p.112 ~ p.117
|
|
|
β-Amyloid Imaging Probes
|
|
Jeong Jae-Min
|
|
|
Abstract
|
|
|
|
Imaging distribution of β-amyloid plaques in Alzheimer’s disease is very important for early and accurate diagnosis. Early trial of the β-amyloid plaques includes using radiolabeled peptides which can be only applied for peripheral β-amyloid plaques due to limited penetration through the blood brain barrier (BBB). Congo red or Chrysamine G derivatives were labeled with Tc-99m for imaging β-amyloid plaques of Alzheimer patient’s brain without success due to problem with BBB penetration. Thioflavin T derivatives gave breakthrough for β-amyloid imaging in vivo, and a benzothiazole derivative [C-11]6-OH-BTA-1 brought a great success. Many other benzothiazole, benzoxazole, benzofuran, imidazopyridine, and styrylbenzene derivatives have been labeled with F-18 and I-123 to improve the imaging quality. However, [C-11]6-OH-BTA-1 still remains as the best. However, short half-life of C-11 is a limitation of wide distribution of this agent. So, it is still required to develop an Tc-99m, F-18 or I-123 labeled agent for β -amyloid imaging agent.
|
|
|
KEYWORD
|
|
|
β-amyloid, alzheimer’s, disease, PET
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|